Zalicus’ Z160 for Chronic Neuropathic Pain Selected as a Top 10 Project to Watch

  Zalicus’ Z160 for Chronic Neuropathic Pain Selected as a Top 10 Project to
  Watch

Zalicus to Present at the Windhover 2012 Therapeutic Area Partnership Meeting

Business Wire

CAMBRIDGE, Mass. -- November 27, 2012

Zalicus Inc. (NASDAQ: ZLCS), a biopharmaceutical company that discovers and
develops novel treatments for patients suffering from pain, today announced
that Z160, its first-in-class, oral, state-dependent, selective N-type calcium
channel (Cav 2.2) blocker in Phase 2 clinical development for chronic
neuropathic pain, has been chosen by Windhover as one of the Top 10
Neuroscience Projects to Watch. Mark Corrigan, MD, CEO of Zalicus, will
provide a summary of Z160 during his presentation at the Windhover 2012
Therapeutic Area Partnership meeting being held at the Westin Copley Place
Boston at 1:30 p.m. ET on Thursday, November 29, 2012 during the Top 10
Neuroscience Projects to Watch session.

"We are delighted that Z160 has been selected as a Top 10 Project to Watch,”
commented Mark H.N. Corrigan, MD, President and CEO of Zalicus. “The lack of
adequate pain control in patients with chronic neuropathic pain represents a
significant unmet need and important opportunity for novel agents with
improved tolerability, enhanced efficacy, and better long-term safety
profiles. We look forward to providing further updates on the clinical
development of Z160 over the coming months.”

About Z160 and N-type Calcium Channel Blockers

Zalicus is currently advancing Z160, a first-in-class, oral, state-dependent,
selective N-type calcium channel (Cav 2.2) blocker, through Phase 2a clinical
development in chronic neuropathic pain. Z160 has demonstrated efficacy in
multiple animal models of neuropathic and inflammatory pain, suggesting that
it has the potential to treat a broad range of chronic pain conditions. In
addition, Z160 was well tolerated in previously conducted clinical trials
involving over 200 subjects. N-type calcium channels have been recognized as
key targets in controlling pain because of their key role in transmitting pain
through the spinal nerves to the brain.

About Zalicus

Zalicus Inc. (Nasdaq: ZLCS) is a biopharmaceutical company that discovers and
develops novel treatments for patients suffering from pain. Zalicus has a
portfolio of proprietary clinical-stage product candidates targeting pain such
as Z160 and Z944, and has entered into multiple revenue-generating
collaborations with large pharmaceutical companies relating to other products,
product candidates and drug discovery technologies. Zalicus applies its
expertise in the discovery and development of selective ion channel modulators
and its combination high throughput screening capabilities to discover
innovative therapeutics for itself and its collaborators in the areas of pain,
inflammation, oncology and infectious disease. To learn more about Zalicus,
please visit www.zalicus.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 concerning Zalicus, its
product candidate Z160, its potential, and its plans for clinical development.
These forward-looking statements about future expectations, plans, objectives
and prospects of Zalicus and Z160 may be identified by words like "believe,"
"expect," "may," "will," "should," "seek," “plan” or “could” and similar
expressions and involve significant risks, uncertainties and assumptions,
including risks related to the clinical development of Z160, the unproven
nature of the Zalicus Ion channel drug discovery technology, and those other
risks that can be found in the "Risk Factors" section of Zalicus' annual
report on Form 10-K on file with the Securities and Exchange Commission and
the other reports that Zalicus periodically files with the Securities and
Exchange Commission. Actual results may differ materially from those Zalicus
contemplated by these forward-looking statements. These forward-looking
statements reflect management’s current views and Zalicus does not undertake
to update any of these forward-looking statements to reflect a change in its
views or events or circumstances that occur after the date of this release
except as required by law.

Contact:

Zalicus Inc.
Justin Renz, 617-301-7575
CFO
JRenz@zalicus.com
or
Gina Nugent, 617-460-3579
gnugent@zalicus.com
 
Press spacebar to pause and continue. Press esc to stop.